BioCentury
ARTICLE | Company News

Management tracks: Elevate hires CSO of regenerative medicine; plus BridgeBio, Acceleron, Flexion, Locana, Nkarta and more

December 11, 2019 1:55 AM UTC
Updated on Dec 11, 2019 at 7:06 PM UTC

ElevateBio LLC hired Melissa Carpenter as CSO of regenerative medicine, a new position. She was president of her own stem cell research consulting firm. ElevateBio emerged from stealth in May with $150 million in series A funding; an executive team led by Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and bluebird bio Inc. (NASDAQ:BLUE) veterans; and plans to build or house cell and gene therapy companies. T cell immunotherapy company HighPassBio and antiviral play AlloVir have since emerged as ElevateBio portfolio companies (see "ElevateBio Launches HighPassBio" and "AlloVir, First to Test ElevateBio's Model").

Genetic diseases company BridgeBio Pharma Inc. (NASDAQ:BBIO) hired Eli Wallace as CSO in residence for oncology. Wallace was CSO of Peloton Therapeutics Inc., which Merck & Co. Inc. (NYSE:MRK) acquired in May...